Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Purvi Chawla

A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Related publications

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2006English

Umbralisib Monotherapy Demonstrates Efficacy and Safety in Patients With Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Registration Directed Phase 2 Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2018English

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

Blood
BiochemistryImmunologyCell BiologyHematology
2014English

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2018English

Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Phase II Open Label Study of the Oral Vascular Endothelial Growth Factor-Receptor Inhibitor PTK787/ZK222584 (Vatalanib) in Adult Patients With Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2013English

Interim Update From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-Pd-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy